Vaccinex logo

VaccinexNASDAQ: VCNX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

09 August 2018

Next earnings report:

20 November 2024

Last dividends:

N/A

Next dividends:

N/A
$9.59 M
-87%vs. 3y high
17%vs. sector
-vs. 3y high
-vs. sector
-125%vs. 3y high
6%vs. sector
-96%vs. 3y high
88%vs. sector

Price

after hours | Wed, 20 Nov 2024 23:45:55 GMT
$3.69+$0.51(+16.04%)

Dividend

No data over the past 3 years
$52.00 K-$5.73 M

Analysts recommendations

Institutional Ownership

VCNX Latest News

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting
globenewswire.com05 November 2024 Sentiment: POSITIVE

Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer.

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
globenewswire.com18 September 2024 Sentiment: POSITIVE

ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock (the “Existing Warrants”) at the reduced exercise price of $5.636 per share, resulting in the issuance of 827,483 shares and the pre-funding of 240,009 shares.

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership
globenewswire.com14 August 2024 Sentiment: POSITIVE

ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease.

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease
globenewswire.com06 June 2024 Sentiment: POSITIVE

Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration.

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com15 May 2024 Sentiment: NEUTRAL

Final patient completed their last visit in the SIGNAL-AD Phase 2a trial evaluating pepinemab for Alzheimer's Disease in early June 2024. $8.2 million of fresh funding was secured in the first quarter.

Why Is Vaccinex (VCNX) Stock Up 26% Today?
InvestorPlace06 October 2023 Sentiment: POSITIVE

Vaccinex (NASDAQ: VCNX ) stock is climbing higher on Friday after the clinical-stage biotechnology company announced insider buying. These insider trading actions were revealed by Vaccinex in a series of filings with the Securities and Exchange Commission (SEC).

Fcmi Parent Now Owns 42.8% of Vaccinex
24/7 Wall Street06 April 2023 Sentiment: NEGATIVE

Fintel reports that Fcmi Parent has filed a 13D/A form with the SEC disclosing ownership of 23.49MM shares of Vaccinex Inc (VCNX).

What type of business is Vaccinex?

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

What sector is Vaccinex in?

Vaccinex is in the Healthcare sector

What industry is Vaccinex in?

Vaccinex is in the Biotechnology industry

What country is Vaccinex from?

Vaccinex is headquartered in United States

When did Vaccinex go public?

Vaccinex initial public offering (IPO) was on 09 August 2018

What is Vaccinex website?

https://www.vaccinex.com

Is Vaccinex in the S&P 500?

No, Vaccinex is not included in the S&P 500 index

Is Vaccinex in the NASDAQ 100?

No, Vaccinex is not included in the NASDAQ 100 index

Is Vaccinex in the Dow Jones?

No, Vaccinex is not included in the Dow Jones index

When was Vaccinex the previous earnings report?

No data

When does Vaccinex earnings report?

The next expected earnings date for Vaccinex is 20 November 2024